liposome doxorubicin
Showing 1 - 25 of 1,409
Desmoid Tumor Trial in GuangZhou (Liposome doxorubicin, Saline Solution)
Recruiting
- Desmoid Tumor
- Liposome doxorubicin
- Saline Solution
-
GuangZhou, Guangdong, ChinaSun Yat-sen University cancer center
Sep 29, 2022
Rhabdomyosarcoma, Child Trial (Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine)
Not yet recruiting
- Rhabdomyosarcoma, Child
- Doxorubicin Hydrochloride Liposome+Irinotecan
- Temozolomide+Irinotecan+Vincristine
- (no location specified)
Jul 13, 2022
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Advanced Breast Cancer Trial in Shijiazhuang (Doxorubicin HCl liposome injection)
Completed
- Advanced Breast Cancer
- Doxorubicin hydrochloride liposome injection
-
Shijiazhuang, ChinaThe Fourth Hospital of Hebei Medical University
Oct 18, 2023
Locally Advanced or Metastatic Solid Tumors Trial in China (IN10018+PLD, IN10018+PLD+Toripalimab)
Active, not recruiting
- Locally Advanced or Metastatic Solid Tumors
-
Anyang, Henan, China
- +6 more
Apr 25, 2023
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Breast Cancer, Ovarian Cancer Trial in Guangzhou (Doxorubicin Hydrochloride Liposome Injection)
Recruiting
- Breast Cancer
- Ovarian Cancer
- Doxorubicin Hydrochloride Liposome Injection
-
Guangzhou, Guangdong, ChinaSun Yat-Sun Memorial Hospital, Sun Yat-Sun University
Mar 8, 2022
Advanced Malignant Tumors Trial in Shanghai (doxorubicin HCl liposome injection)
Recruiting
- Advanced Malignant Tumors
- doxorubicin hydrochloride liposome injection
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 28, 2022
Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma Trial in Guangzhou (PD-1 inhibitor, PD-1
Recruiting
- Classical Hodgkin Lymphoma
- Refractory or Relapsed Classical Hodgkin Lymphoma
- PD-1 inhibitor
- PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
-
Guangzhou, Guangdong, China
- +2 more
May 6, 2022
Relapsed Sarcomas Trial in Cleveland (Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil))
Not yet recruiting
- Relapsed Sarcomas
- Disulfiram
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Apr 18, 2022
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)
Active, not recruiting
- Invasive Breast Carcinoma
- Triple-Negative Breast Carcinoma
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Feb 18, 2022
Sarcoma Trial in Baltimore, Minneapolis (biological, drug, procedure, radiation)
Active, not recruiting
- Sarcoma
- pegfilgrastim
- +5 more
-
Baltimore, Maryland
- +1 more
Mar 25, 2022
Efficacy and Safety Trial in Zhejiang (pegylated liposomal doxorubicin, paclitaxel, Carboplatin)
Active, not recruiting
- Efficacy and Safety
- pegylated liposomal doxorubicin
- +2 more
-
Zhejiang, Hangzhou, ChinaWomen's Hospital School Of Medicine Zhejiang University
Jul 14, 2022
Breast Cancer, Chemotherapeutic Toxicity Trial in Hanzhou (Liposomal doxorubicin + Cyclophosphamide vs Docetaxel +
Recruiting
- Breast Cancer
- Chemotherapeutic Toxicity
- Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
-
Hanzhou, Zhejing, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
Apr 7, 2022
Breast Cancer Trial in Worldwide (Liposomal doxorubicin HCl, Cyclophosphamide, Trastuzumab)
Completed
- Breast Cancer
- Liposomal doxorubicin hydrochloride
- +4 more
-
Kufstein, Austria
- +21 more
Jun 21, 2022
Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))
Recruiting
- Breast Cancer
- pegylated liposomal doxorubicin (PLD)
- +5 more
-
Guandong, Guangdong, ChinaSunyat-sen Memorial Hospital
Feb 17, 2022
Breast Cancer and Ovarian Cancer Trial (SPARC-08-038, Ref-08-038)
Completed
- Breast Cancer and Ovarian Cancer
- (no location specified)
Jul 22, 2021
Metastatic Breast Cancer Trial in Morgantown (DOXIL, Abraxane)
Completed
- Metastatic Breast Cancer
-
Morgantown, West VirginiaClinical Trials Research Unit, West Virginia University
Dec 22, 2020